Tag : MODERATE-TO-SEVERE HAND AND FOOT INVOLVEMENT

NEWS AND PERSPECTIVE

Dupilumab receives FDA approval for AD with moderate-to-severe hand and foot involvement based on data from the LIBERTY-AD-HAFT trial
Despite being approved for the treatment of moderate-to-severe atopic dermatitis (AD), dupilumab’s efficacy in treating patients with atopic hand and foot dermatitis had not been evaluated. The LIBERTY-AD-HAFT trial demonstrated dupilumab’s efficacy and safety in treating patients with AD with moderate-to-severe hand and foot involvement. Based on the study results, the United States (US) Food and Drug Administration (FDA) updated the label of dupilumab to include AD with moderate-to-severe hand and foot involvement.